New Zealand markets closed

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
32.59-1.55 (-4.54%)
At close: 04:00PM EST
32.59 0.00 (0.00%)
After hours: 04:42PM EST
Full screen
Loading interactive chart…
  • GlobeNewswire

    Grant of Restricted Stock Units and Warrants to Employees in Genmab

    Company Announcement COPENHAGEN, Denmark; January 25, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 15,045 restricted stock units and 17,841 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price

  • GlobeNewswire

    Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021

    Company Announcement Net sales of DARZALEX® in 2021 totaled USD 6,023 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 25, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 6,023 million in 2

  • GlobeNewswire

    Genmab and Synaffix Enter into License Agreement for ADC Technology

    Media Release Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologiesGenmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapiesSynaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single digit royalties on sales of successfully commercialized therapies COPENHAGEN, Denmark and AMSTERD